Oral Sessions (Day1, Day2, Day3)
Poster Presentations
- Day 3, May 21(Fri.) Room P2 (Zoom)
-
3P-41 PDF
Plasma Amyloid-β Biomarker Performance using MALDI-TOF MS with the Automated Immunoprecipitation
Abnormal amyloid-β (Aβ) deposition in the brain has been defined as the earliest pathological change of Alzheimer disease (AD). Using immunoprecipitation (IP) combined with MALDI-TOF MS, we have previously reported that the composite biomarker, which is a combination of APP669-711/Aβ1-42 ratio and Aβ1-40/ Aβ1-42 ratio in human plasma, correlates with amyloid PET status. In this study, we constructed an automated IP system for high-throughput analysis and then evaluated the biomarker performance by measuring 41 Aβ+ and 55 Aβ- subjects classified using PET with PIB tracer. In a receiver operating characteristic (ROC) analysis, MALDI-TOF MS with the automated IP showed high area under the ROC curves and accuracy in the three biomarkers.